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1078–5884/00Endoluminal Angioplasty of the Popliteal Artery. Review of
54 Consecutive Patients
A. Abdul Raouf,* Y. Rouleau, A. Clement, P. Le Roux, P. Genay and J.-B. RiccoService of Vascular Surgery, CHD Les Ouclairies, 85925 La Roche sur Yon, FranceAim. To determine the results of endoluminal angioplasty for occlusive or stenotic lesions of the popliteal artery.
Methods. Retrospective study of symptomatic patients having popliteal occlusive lesions treated by endoluminal balloon
angioplasty. All patients underwent systematic preoperative and postoperative color duplex scan and preoperative
angiography. The principal endpoints were primary and primary assisted patency.
Results. Fifty-four percutaneous endoluminal angioplasties of the popliteal artery, including six procedures with stents,
were performed in 50 patients. In all cases, the superficial femoral artery was patent and without significant stenosis.
Primary patency for the entire cohort was 57.4G6.7% at 1 and 2 years. Primary assisted patency was 86.3G4.8% at 1 year,
and 79.1G5.9% at 2 years.
The results of angioplasty appeared to be better in patients with intermittent claudication when compared to patients with
critical limb ischaemia, (pZ0.0006). Angioplasty of single occlusive lesions had a better prognosis than that of multiple
occlusive lesions (pZ0.01). Results of angioplasty were better at the below-knee and median popliteal artery than at the
femoro-popliteal junction or in the above-knee popliteal artery (pZ0.03). Tibial run-off and isolated popliteal stenosis
versus isolated popliteal thrombosis did not seem to affect primary patency rate.
Conclusion. Results of angioplasty of the popliteal artery are acceptable for claudicants, especially those with TASC-A
lesions and those with lesions in the distal two thirds of the popliteal artery.Keywords: Balloon dilatation; Popliteal artery; Stenosis; Primary patency; Primary assisted patency.Introduction
The results of endoluminal angioplasty of the popliteal
artery have rarely been studied specifically. In most
cases, authors have studied the results of angioplasty
of the superficial femoral artery with that of the
popliteal artery.1–3 Only two studies focusing specifi-
cally on angioplasty of the popliteal artery can be
found in the literature. The first, performed by
Steinkamp4 concerned 215 cases, and compared the
results of endoluminal angioplasty with a balloon
catheter with those of laser endoluminal angioplasty.
The second study, performed by Strecker,5 evaluated
the efficacy of flexible tantalum stents in treating
residual stenoses after angioplasty of the popliteal
artery. In most studies, results have focused on
angioplasty for the entire femoral and popliteal
segment: In this setting, primary patency rate, varies
from 22 to 81%, after 1-year follow-up. The aim of our
study was to determine the 2-year results ofng author. A. Abdul Raouf, MD, Service of Vascular
Les Ouclairies, 85925 La Roche sur Yon, France.
: ayman.abdulraouf@wanadoo.fr
0610 + 04 $35.00/0 q 2005 Elsevier Ltd. All rights reserendoluminal angioplasty for occlusive lesions limited
to the popliteal artery.Methods
This was a retrospective study of 50 patients having 54
popliteal angioplasties between January 1997 and
April 2002. All these patients were symptomatic with
intermittent claudication (ICZ26) or critical limb
ischemia (CLIZ28). All patients had an occlusion or
a significant stenosis of the popliteal artery. Before
treatment, all patients had a duplex ultrasonography,
with colour imaging, and angiography of the lower
limbs. Lesions were classified according to TASC
criteria. Patients excluded from the study were those
presenting with acute ischemia. In contrast, patients
presenting with a simultaneous significant stenosis of
the iliac or common femoral artery, were included in
the study. Percutaneous transluminal angioplasty
(PTA) was performed by a vascular surgeon in the
operating room, using a conventional guidewire and
angioplasty balloon catheter technique withoutEur J Vasc Endovasc Surg 30, 610–613 (2005)
doi:10.1016/j.ejvs.2005.06.014, available online at http://www.sciencedirect.com onved.
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each patient was given 50 IU/kg of heparin intrave-
nously and if tolerated 160 mg aspirin daily thereafter.
Postoperative criteria of success was defined: By relief
or substantial improvement of claudication with an
increase in walking distance by at least 50%, resolution
of rest pain and limb salvage in patients with tissue
loss. Patency was determined by duplex scan,
performed routinely at 1, 6, 12 months after surgery
and every year thereafter. Special emphasis was given
to the site of angioplasty to detect any occlusion or
significant restenosis with cross sectional area reduced
by 70% or more. Angiograms were performed
whenever significant restenosis or occlusion was
seen by duplex. Ankle-brachial index was not
obtained routinely. Failure of angioplasty was defined
by persistence or recurrence of a significant popliteal
stenosis by duplex scan, with or without worsening of
clinical symptoms. Analysis of primary patency and
primary assisted patency, was undertaken considering
the following parameters: Preoperative symptoms,
TASC classification (A, B, C) in the femoro-popliteal
segment, and existence of single or multiple lesions,
length of the lesion, thrombotic or stenotic lesion,
location of the lesion on the popliteal artery, above
knee, below knee or retroarticular. Finally, tibial run-
off (number of patent arteries in the leg) was analysed.
The Kaplan–Meier method was used to calculate the
cumulative patency rate for individual variables and
subgroups. The survival curves were compared by the
log rank (Mantel–Cox) test.Results
The clinical characteristics of these patients are shown
in Table 1. Fifty-four endoluminal angioplasties of the
popliteal artery were performed in 50 patients havingTable 1. Patients and popliteal lesions characteristics
Characteristics Patients (%)
Male 34 (68)
Risk factors
Diabetes 24 (48)
Hypertension 27 (54)
Dyslipidemia 11 (22)
Current smokers 13 (26)
Ischemic heart disease 15 (30)
History of vascular disease 7 (14)
ASA classification
ASA 1 2 (4)
ASA 2 17 (34)
ASA 3 28 (56)
ASA 4 3 (6)
Age 73 years (48–93)
Length of popliteal lesion 12 mm (2–80 mm)65 occlusive lesions (Table 2). Forty-four patients had a
single occlusive lesion and 10 patients had multiple
occlusive lesions, with two popliteal stenoses in nine
patients, and three popliteal stenoses in one patient.
Forty patients underwent angioplasty and 14 patients
underwent recanalisation (the median length of
occlusion in this series was 2.5 cm (range 0.5–8 cm)).
Ultra thin angioplasty balloons (Boston Scientific)
were used in all cases, the diameter of the balloon
was 4 mm in 27 cases (41%) and 5 mm in 29 cases
(45%). We also used 3 mm balloons twice (3%) and
6 mm balloons seven times (11%). Three haematomas
occurred at the puncture site with one false aneurysm.
Per-operative mortality was nil. Following initial
angioplasty, we observed nine residual stenoses,
from 20 to 50%, that were left untreated with one
significant restenosis (11%) at 1 year. Follow-up was
for 2 years in all patients. Two major amputations were
needed during the first year in patients with critical
limb ischemia (CLI), and two failures (4%) were
treated by femoropopliteal or tibial bypass. Five
concomitant lesions of the iliac or common femoral
artery were treated, i.e two iliac angioplasties, two
common femoral endarterectomies, and one ilio-
femoral bypass. Three of these patients remain
asymptomatic, one patient had a popliteal restenosis
and one patient died during follow-up. In addition,
two infrapopliteal lesions were treated simul-
taneously: One patient remains asymptomatic and
one patient had a recurrent popliteal stenosis at 1 year.
The primary patency rate, for the entire cohort was
57.4G6.7% at 2 years. Primary assisted patency rate
was 86.3G4.8% at 1 year, and 79.1G5.9% at 2 years.
Four patients (8%) were lost to follow-up (three
patients by 1-year and one by 2 years). Eleven patients
(22%) died during follow-up. Among the 13 patients
with a restenosis, primary assisted patency after
repeated angioplasty was 69%, (six patients under-
went two angioplasties, one patient underwent three
consecutive angioplasties and two patients a bypass).
Six nitinol self-expanding stents were used, two to
treat a restenosis and four to treat a popliteal
dissection during the initial procedure. These stents
were positioned at the level of the upper popliteal
artery. No stents were positioned in middle popliteal
artery or lower popliteal artery. Five stents remain
patent during follow up and one stent had occluded
by 1 year.
Primary patency at 2-year was higher in patients
with intermittent claudication (87.0G7.0%) than in
patients with critical limb ischemia (38.2G10.8%) pZ0.
0006 (Fig. 1). TASC type A lesions appeared to have a
better patency (73.4G7.6%) than type B–C lesions
(40.4G13.4%) pZ0.09. Angioplasty of single occlusiveEur J Vasc Endovasc Surg Vol 30, 12 2005
Table 2. Patency at 2-year according to the patient or lesion characteristics
n % Primary patency rateGSE p Value*
Indications
Intermittent claudication 26 48 87.0G7.0
Critical limb ischemia 28 52 38.2G10.8 0.0006
TASC popliteal classification
Type A 36 67 73.4G7.6
Type B–C 18 33 40.4G13.8 0.09
Number of lesions
Isolated 44 81 71.7G7.3
Multiple 10 19 26.7G16.0 0.01
Anatomical location
Median and BK popliteal 37 57 77.6G8.1
AK popliteal 28 43 41.5G9.1 0.03
TASC infrapopliteal lesions
Type B 11 20 77.8G13.9
Type D 43 80 60.2G8.1 NS
Type of isolated lesion
Stenosis 31 70 75.1G8.2
Thrombosis 13 30 64.6G14.3 NS
Length of lesion (cm)
!3 59 91 59.1G7.0
R3 6 9 41.7G22.2 NS
Primary patency rate for the entire cohort was 57.4G6.7% at 2-year. BK, below knee; AK, above knee; NS, non-significant.
* Log rank test.
A. Abdul Raouf et al.612lesions had a better primary patency rate at 2-year
(71.7G7.3%) than that of multiple occlusive lesions
(26.7G16.0%) pZ0.01. Angioplasty produced better
results in the lower and middle popliteal artery
(77.6G8.1%) than at the femoropopliteal junction or
in the upper popliteal artery (41.5G9.1%) pZ0.03.
However, length of lesions, tibial run-off and
stenoses compared to occlusion, did not influence
primary patency rate.Fig. 1. Cumulative primary patency rate (Kaplan–Meier
method) for 26 patients with intermittent claudication and 28
patients with critical ischaemia having angioplasty of the
popliteal artery. Numbers indicate patients at risk at each
time interval.
Eur J Vasc Endovasc Surg Vol 30, 12 2005Discussion
Angioplasty of the popliteal artery remains contro-
versial. Many questions remain concerning its intrinsic
value, including indications and prognostic factors
influencing long-term patency. The length of occlusive
lesions is apparently a significant factor affecting
primary patency. However, the definition of a short
lesion varies from one report to another; it may be less
than 2 cm, 3 cm, even 5 or 7 cm and sometimes 10 cm.
This criterion was not significant in our series, but
most lesions were less than 3 cm with a mean length of
1.2 cm. It is important to note that several authors have
used fibrinolysis to reduce the length of occlusive
lesions.1,2,6–10 Strecker5 evaluated the efficacy of
flexible tantalum stents in the popliteal artery in 32
patients, for the treatment of residual stenoses of more
than 50% after angioplasty for stenosis (17 cases) and
thromboses (15 cases) of the popliteal artery. Strecker5
reported primary patency rates at 1 and 2 years of 81
and 74%, respectively. In this series,5 primary patency
rate at 1 year was better for stenoses than for
occlusions; however, this difference was not signifi-
cant. In keeping with the results of Alba¨ck, Cormier
and Henry,3,11,12 we did not find in our series any
significant difference between these two groups.
Henry3 found that restenosis was more common in
the distal third of the superficial femoral artery (SFA)
and in the popliteal artery as compared with the
proximal two-thirds of the SFA. We found that below
knee and retroarticular popliteal arteries were more
suitable for an endovascular procedure than above
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From our series, we can conclude that angioplasty of
the femoropopliteal segment is acceptable, with best
results at the distal two-thirds of the popliteal artery.
This finding might be explained by a reduced mobility
following knee flexion of the artery at this level
compared with the upper politeal artery.
There is no consensus regarding the use of popliteal
angioplasty to treat claudication, but even if PTA is a
commonly performed procedure at this level, Per-
kins13 failed to show any significant benefits from
angioplasty in a controlled trial comparing exercise
training to angioplasty. Therefore, Perkins13 recom-
mends exercise training as initial management in stable
claudicants with multifocal stenosis of the superficial
femoral artery. In contrast, Whyman14 found that PTA in
patients with claudication due to single short superficial
femoral artery stenosis offered a better short term
outcome than best medical treatment alone. It is true
that improvement in symptoms with exercise is
common but improvement may not show for up to a
year, whereas improvement of symptoms after a
successful angioplasty can be immediate.
Our results show that PTA is an interesting alternative
to open surgical revascularization, for short TASC A
lesions, with an acceptable patency rate at medium term
follow-up. However, this endovascular approach should
be used with caution, because of the risk of worsening of
the symptoms in the event of failure.12,15
For treatment of critical limb ischemia, the primary
patency rate in our series was only 38.2G10.8% at 2
years. However, only half of these patients had TASC
type A lesions, the other half had type B–C with
extensive or multiple lesions.
It is logical that the results of angioplasty should be
influenced by the type and severity of the occlusive
lesion. This has been confirmed by several studies of
femoro-popliteal stenting.1,10,11,16 In our series, the
patency at 2 years was significantly better for single
stenoses (71.7G7.3%) than for multiple stenoses
(26.7G16.0%). In contrast, we did not show any
difference in patency rates following the treatment of
either isolated short thromboses or stenoses.Conclusions
Angioplasty of the popliteal artery is a simple
technique which merits further evaluation. It could
become the technique of choice for TASC A lesions of
the distal two thirds of the popliteal artery in patients
with intermittent claudication. However, angioplasty
cannot be recommended in patients with multiple
stenoses, located at the level of the femoropoplitealjunction and upper popliteal artery or for patients with
TASC B–C lesions.References
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